Serum C-reactive Protein Level Predicts Overall Survival for Clear Cell and Non-Clear Cell Renal Cell Carcinoma Treated with Ipilimumab plus NivolumabYusuke Yano, Haruhito Azuma, Takuya Tsujino et al.|Cancers|2022Cited by 21
Predicting time to castration resistance with androgen-receptor signaling inhibitors in hormone-sensitive prostate cancer: data from ULTRA-Japan ConsortiumTaizo Uchimoto, Haruhito Azuma, Kengo Iwatsuki et al.|International Journal of Clinical Oncology|2024Cited by 12
Prognostic Impact of Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma Treated With Nivolumab Plus Ipilimumab: A Multicenter Retrospective StudyTakuhisa Nukaya, Ryoichi Shiroki, Kiyoshi Takahara et al.|Clinical Genitourinary Cancer|2023Cited by 8
Concurrent palliative radiation with pembrolizumab for platinum-refractory urothelial carcinoma is associated with improved overall survivalKeita Nakamori, Haruhito Azuma, Shogo Yamazaki et al.|Clinical and Translational Radiation Oncology|2022Cited by 7
<scp>Real‑world</scp> survival outcome comparing abiraterone acetate plus prednisone and enzalutamide for <scp>nonmetastatic castration‐resistant</scp> prostate cancerTakuya Tsujino, Haruhito Azuma, Satoshi Tokushige et al.|Cancer Medicine|2023Cited by 4